56 results about "Hypoglycemia" patented technology

Disclosed herein are apparatuses and methods that can provide a delayed bolus calculator for use in closed loop diabetes therapy that can account for additional factors not taken into account in regular meal bolus calculations when a user wants to deliver a meal bolus a period of time after a meal was consumed. A delayed bolus calculator can enable the user to enter a period of time since the meal was consumed in addition to the number of carbohydrates consumed in a meal. This enables the system to account for the amount of increased insulin from the closed loop algorithm in response to the meal and / or the time since the meal to ensure that the risk of hypoglycemia is mitigated while still reducing hyperglycemia.

The invention provides an intelligent insulin closed-loop infusion system for type 1 diabetes mellitus, and relates to the technical field of diabetes mellitus treatment equipment. The system comprises a blood glucose monitoring module, a control module, an insulin infusion module, a user interaction module, a wireless communication module and a power module, and closed-loop precise infusion of insulin is achieved through cooperation of the multiple modules. Wherein a closed-loop algorithm based on a dynamic basic rate formula is arranged in the control module, and the insulin infusion amount can be dynamically adjusted in combination with an LSTM blood glucose prediction model and a metabolic parameter least square method updating unit; the insulin infusion module adopts a micro peristaltic pump controlled by PWM (Pulse Width Modulation) and a current monitoring type blockage detection unit, so that the infusion precision and safety are guaranteed. According to the system, the blood glucose standard reaching time proportion can be increased to 78%, the hypoglycemia occurrence frequency is reduced to 0.8 times per week, the system is remarkably superior to a traditional insulin pump and a simple closed-loop system, meanwhile, the system has the advantages of being long in sensor service life and low in power consumption, and the treatment convenience and safety of type 1 diabetes patients are improved.

Certain aspects of the present disclosure provide systems and techniques for rapid detection of repetitive metabolic events in a host based on measured analyte data provided by an analyte monitor worn by the host. An example system is configured to obtain measured glucose data of the host. A subset of the measured glucose data is determined, based on performing a filtering operation on the measured glucose data. A respective range of a likelihood of an occurrence of a metabolic is determined for each value within the subset of the measured glucose data. For at least one value within the subset of the measured glucose data, a state of the metabolic event is determined based in part on at least one of an upper bound or a lower bound of the respective range corresponding to the at least one value within the subset of the measured glucose data.

The present invention relates to formulations of glucagon analogues or pharmaceutically acceptable salts and / or derivatives thereof; and their medical use, e.g. in the treatment of hypoglycemia. In particular, the present invention relates to stable aqueous liquid formulations of glucagon analogues comprising a combination of excipients that make them suitable for long-term storage as liquids and capable of being used in single dose (SD) or multiple dose (MD) formulations.

The present invention relates to a biocompatible tattoo ink that changes color in response to varying glucose levels in the bloodstream, providing a continuous monitoring method for individuals with diabetes. The ink contains glucose-sensitive agents that cause the tattoo to change from green (normal glucose levels) to red (high glucose levels) or blue (low glucose levels). Additionally, the ink shifts back to green when blood glucose returns to normal from either hyperglycemia or hypoglycemia. This provides a real-time visual indicator of glucose levels and enables users to monitor their health without additional equipment.

The present invention belongs to the technical field of insulin derivatives. Disclosed are a phenylboronic-acid-based insulin derivative, and a preparation method therefor and the use thereof. The provided phenylboronic-acid-based insulin derivative has a good glucose-responsive release function, wherein the phenylboronic acid group binds to a glycosyl protein to generate a phenylboronic acid ester bond, thereby generating an insulin and glycosyl protein complex in situ in blood. When the concentration of glucose in the blood is high, the glucose specifically cleaves the phenylboronic acid ester bond, thereby releasing the insulin. The provided phenylboronic-acid-based insulin derivative achieves stable and rapid glucose-responsive insulin release, which can steadily and persistently maintain the blood glucose of a diabetic subject within the normal range with almost no occurrence of hypoglycemia.

The application discloses corn silk glucan, a structure formula of which is [→4)-β-D-Glcp-(1→]n, wherein n is 6-60, and a molecular weight range is 1-9.8 kDa. By extracting effective components in corn silk, an extract is obtained, the extract is precipitated by 30-90% ethanol, corn silk crude polysaccharide is obtained, and after the corn silk crude polysaccharide is dissolved, the corn silk crude polysaccharide is sequentially subjected to biological membrane dialysis, ion exchange resin column and HPLC-ELSD separation and purification, and corn silk glucan is obtained. The corn silk glucan and zeaxanthin are compounded to form a glucan compound, the glucan compound can stabilize insulin and improve the activity of the insulin in mouse islet cells, and the glucan compound has 2-5 times stronger hypoglycemic activity than that of zeaxanthin alone, and therefore, the glucan compound has important significance for researching new hypoglycemic drugs or health-care food for assisting hypoglycemia.

Exemplary embodiments account for differing needs of a user over the menstrual cycle of the user to better control the blood glucose concentration of the user. The exemplary embodiments may be realized in control systems for medicament delivery devices that deliver medicaments, such as medicaments that regulate blood glucose concentration levels. Examples of such medicaments that regulate blood glucose concentration levels include insulin, glucagon, and glucagon peptide-1 (GLP-1) agonists. The exemplary embodiments are able to better tailor the dosages of the medicament delivered to the user with the medicament delivery device to reduce the risk of hyperglycemia and hypoglycemia and help reduce blood glucose concentration excursions.

Provided are related to antibodies or antigen-binding fragments thereof that specifically bind to GLP-IR, and uses thereof. The antibodies or antigen-binding fragments can antagonize the activation of GLP-IR by endogenous or exogenous GLP-1, and can be used for the diagnosis, prevention and / or treatment of GLP-IR-associated or hypoglycemia-associated diseases or disorders.

This invention discloses an interlocking drug infusion device, comprising a drug reservoir for containing drugs, a piston and a screw disposed within the reservoir; a drive wheel connected to the screw, which drives the piston forward by rotating the drive screw; a drive unit that moves in the drive direction to drive the drive wheel to rotate; a driver electrically connected to the drive unit, which, when energized, provides power to the drive unit in the drive direction; a program module electrically connected to the driver, which provides a first drive instruction to control the driver to perform periodic power output; and a position detection module for determining the periodic drug infusion volume. When the drug infusion volume reaches a set threshold, the position detection module and / or the program module provide a second drive instruction to the driver. The program module and the position detection module physically form a synchronous interlocking mechanism to prevent over-infusion in the event of electronic component or preset program failure, thus preventing the risk of hypoglycemia or even coma.

Disclosed herein are methods of treating and ameliorating hyperinsulin hypoglycemia using sodium dependent glucose transporter (SGLT) 1 inhibitor compounds and compositions comprising them.

The application discloses a new type of hapten and fatty acid double modified long-acting hypoglycemic BimBH3 mimetic peptide compound targeting PTP1B as well as a preparation method and application thereof. The structural general formula of the Bim BH3 mimetic peptide is shown as formula I: wherein the compound is derived from a core region peptide segment of a Bim-BH3 domain, a non-natural amino acid is used to replace the second amino acid by site-specific substitution to increase the stability of the peptide segment against DPP-4 enzyme, and a long-chain fatty acid (hexadecanoic acid or octadecanedioic acid) is conjugated to the N terminal to modify to ensure better PTP1B inhibitory activity, so that the BimBH3 mimetic peptide has longer duration and higher activity and plays a role in hypoglycemia by inhibiting the target PTP1B. The compounds are prepared by using 2-CTC resin by polypeptide solid-phase synthesis method, and the crude product is cut, purified and freeze-dried to obtain a pure target compound.

The application belongs to the technical field of medicine production and relates to responsive sustained / controlled release microspheres and a preparation method and application thereof.The responsive sustained / controlled release microspheres comprise, by weight fraction, 160-200 parts of acetalized dextran, 40-80 parts of polylactic acid-glycolic acid copolymer, 10-30 parts of a drug, 3-7 parts of glucose oxidase and 0.5-1.5 parts of catalase; the mass ratio of the acetalized dextran and the polylactic acid-glycolic acid copolymer is 3-5:1.The microspheres can release insulin responsively according to blood glucose, once administration can stabilize blood glucose for 20 hours, and can ensure safety while effectively reducing blood glucose, and will not cause a series of life-threatening symptoms such as hypoglycemia due to excessive insulin injection.The blood glucose maintenance cycle can be adjusted according to the dose of the microspheres, and the purpose of long-term stable blood glucose is achieved.At the same time, the size and performance of the microspheres are uniform and stable.

This invention relates to the field of blood glucose detection technology and discloses a depression compensation method and system for CGM sensors. The method extracts temporal and physiological features from the acquired blood glucose-related current signals to generate fused feature data. Based on preset temporal dimension rules, it first determines whether the depression is short-term, accurately identifying the temporal features of non-physiological depressions. This enables effective identification of non-physiological signal depressions at night. The dual-dimensional judgment rules achieve accurate differentiation of signal causes. When a short-term depression is determined in the temporal dimension, it is verified by physiological dimension rules. This dual-layer identification logic of initial screening of temporal features and verification of physiological features avoids signal confusion, reduces the false positive rate, prevents the risk of missed hypoglycemia or erroneous intervention, and solves the technical problem that nighttime monitoring easily miscorrects true hypoglycemia signals or misjudges non-physiological depressions as hypoglycemia.

The utility model relates to the technical field of medical instruments, in particular to a visual hypoglycemia prevention and treatment box. The visual hypoglycemia prevention and treatment box comprises a box body, a box cover and a sealing cover assembly, and the box cover is hinged to an opening in the top of the box body; a cavity is formed in the box body, a partition plate is arranged in the box body and divides the cavity in the box body into a first cavity body and a second cavity body, and the second cavity body is used for containing propaganda and education lists; the interior of the first cavity is divided into a plurality of storage cavities for storing sugar-containing food through partition mechanisms, the sugar content of the sugar-containing food is gram, the sealing cover assembly is used for covering the storage cavities, the sealing cover assembly is provided with a plurality of drying agent storage cavities in one-to-one correspondence with the storage cavities, and a plurality of air outlet holes are formed in the inner bottom walls of the drying agent storage cavities; the desiccant storage cavity is used for storing desiccant. When a patient suffers from hypoglycemia, the patient can be ensured to timely and accurately eat 15g of sugar-containing food, so that the retested blood glucose can reach the standard.

A continuous glucose monitor (CGM)-driven basal insulin titration system and method for patients with Type 2 Diabetes can be adapted to the needs and concerns of subjects just starting on basal insulin therapy. The method uses as inputs historical CGM data, basal insulin dose information, reports of hypoglycemia, and past recommendations and generates an adjusted insulin dose along with a report advising whether to continue the titration process, or to stop. The method can generate a new recommendation on a regular basis (e.g., each day) until it determines an adequate, consistent dose size.

Techniques disclosed herein relate to safe correction boluses. In some embodiments, the techniques involve obtaining a plurality of sensor glucose readings for a patient. The techniques may further involve determining, based on the plurality of sensor glucose readings that the patient has consumed a meal. The techniques may further involve in response to determining the patient has consumed the meal, reducing a hypoglycemia threshold from a first value to a second value lower than the first value. The techniques may further involve determining a correction bolus dosage based on the reduced hypoglycemia threshold.

The invention relates to the technical field of medical equipment, and discloses a diabetic insulin infusion device which comprises a mounting shell, a medicine storage shell is fixedly mounted in the middle of the top end of the mounting shell, a containing cavity used for containing insulin is formed in the medicine storage shell, and a protective shell is detachably connected to one side of the top of the mounting shell; a driving motor is fixedly mounted on the inner side of the protective shell, a fixed seat is fixedly connected to the inner bottom wall of the capacity cavity, a movable rod is slidably connected to an inner through hole of the fixed seat, a rotating shaft is movably connected to the interior of the capacity cavity through a bearing, and a driving part is fixedly connected to the middle side of the exterior of the rotating shaft; and the inner side of the driving piece is rotationally connected with a hinge rod. Through the targeted anti-blocking design, the continuity and smoothness of insulin delivery in the infusion tube can be continuously guaranteed, abnormal blood glucose fluctuation caused by infusion interruption and the risk of hypoglycemia caused by blind supplementary infusion after blockage is removed are avoided, and the stability and accuracy of insulin infusion are remarkably improved.

The present application relates to the biomedical field, specifically relates to a glucose-responsive empagliflozin microneedle delivery system and application thereof.The glucose-responsive empagliflozin microneedle delivery system of the present application is characterized in that the microneedle delivery system is a microneedle patch, comprising a substrate and a microneedle array arranged on the substrate; the microneedle in the microneedle array contains glucose-responsive empagliflozin nanoparticles CB@E or PCB@E.The present application has the following technical effects: the empagliflozin nanoparticles of the present application have precise glucose-responsive drug release performance.The microneedle drug delivery system of the present application has the effect of long-term control of blood glucose.In a T2DM rat model, MN@CB@E exhibits long-acting blood glucose control effect, can reduce blood glucose to normal level within 4h and maintain for 24h, and the hypoglycemic duration is significantly better than that of subcutaneous injection of free empagliflozin (only maintains for 6h), and there is no risk of hypoglycemia after administration to healthy rats.

The invention provides a hypoglycemia tumble early warning system based on bioelectrical impedance mode classification, relates to the technical field of mode recognition, and constructs a collaborative early warning system integrating motion artifact compensation, hybrid detection, dynamic decision and closed-loop adaptive control. Multiple limitations in the aspects of accuracy, power consumption, decision-making sensitivity and execution intelligence in the prior art are successfully solved; on the premise of maintaining the long-term cruising ability of the wearable device, the false alarm rate caused by factors such as motion artifacts can be reduced through cooperative verification of passive monitoring and active detection; through dynamic activation and nonlinear fusion decision, the early warning sensitivity and accuracy of acute risk events are improved; and through closed-loop control with time sequence context perception, more humanized and efficient early warning intervention is realized, and finally, a really reliable hypoglycemia falling risk early warning solution from trend perception to state confirmation is provided for a user.

The application provides a method and device for dynamically predicting hypoglycemia risk of inpatients, and belongs to the field of medical artificial intelligence and digital health technology. The method comprises the following steps: acquiring multi-source inpatient medical data conforming to diagnostic record standards, pre-processing the inpatient medical data according to predetermined prediction factors, constructing a daily prediction unit for each patient, extracting the inpatient medical data within a preset time observation window according to a preset prediction time point based on the daily prediction unit, and analyzing and processing the inpatient medical data to obtain a feature data set with a time dimension of each day; inputting the feature data set into a hypoglycemia risk prediction model that has been trained according to the inpatient medical data, and outputting the risk probability of a hypoglycemia event of a corresponding patient within a preset future time window; and converting the risk probability into auxiliary decision-making information for hypoglycemia intervention according to a preset prediction result conversion rule. The short-term dynamic prediction of the hypoglycemia risk of inpatients is realized.

The application belongs to the technical field of composite materials, and particularly discloses a preparation method and application of a stress-resistant and immunity-enhancing preparation for piglets, which is prepared by using sodium iron chlorophyll and sodium selenium-rich acid as core blood supplement elements, collocating an astragalus polysaccharide and a cordyceps polysaccharide compound polysaccharide system, combining functional oligosaccharides, antibacterial peptides and probiotics to construct an intestinal microecological regulation module, and supplementing with composite amino acids and vitamins to form a nutritional synergistic system, and is prepared through gradient sugar molecule inclusion, low-temperature microcapsule embedding and other innovative processes, so that the physical energy, qi and blood are supplemented simultaneously. The preparation can effectively reduce the incidence of hypoglycemia in newborn piglets, improve the disease resistance and immunity of the piglets, relieve weaning stress, improve the weaning survival rate and weaning weight, and simultaneously improve the nutritional supply of perinatal sows, reduce postpartum fatigue of the sows, improve milk quality and indirectly help the growth of the piglets.

The present application discloses the use of SUR2 receptor modulators. In the present application, SUR2 receptor modulators (e.g. MLC1) can be combined with skeletal muscle cell K ATP SUR2 specific binding on potassium ion channel, thus enhancing intracellular calcium signal, increasing glucose uptake of skeletal muscle cell and reducing blood glucose, and thus can be used as a therapeutic drug for diabetes; SUR2 receptor modulators selectively bind to SUR2 through a non-islet β cell dependent mechanism, and have no inhibitory effect on islet β cell SUR1 receptor, and thus can effectively avoid hypoglycemia while reducing blood glucose, and have small side effects.

The invention discloses an insulin pump control method and system based on blood glucose data, and relates to the technical field of insulin infusion control, and the method comprises the steps: obtaining real-time blood glucose sequence data and historical infusion record data, and carrying out the preprocessing; constructing an insulin pharmacokinetic attenuation model to calculate an in-transit insulin residual activity value; inputting the standardized blood glucose time series data into a Bayesian neural network prediction model to generate prediction uncertainty distribution parameters; calculating a prediction confidence index according to the prediction variance and comparing the prediction confidence index with a threshold value to obtain a confidence judgment result; selecting a dose optimization strategy or a conservative control strategy according to a confidence coefficient judgment result to calculate an insulin infusion dose; infusion is executed, and historical records are updated; the prediction uncertainty is quantified through the Bayesian neural network, the in-transit insulin activity is accurately modeled in combination with the pharmacokinetic model, and the control strategy is dynamically switched according to the confidence, so that the control error amplification caused by prediction misjudgment is effectively avoided, and the delayed hypoglycemia caused by the insulin superposition effect is prevented.

The utility model discloses an early warning device for hypoglycemia monitoring relates to the blood glucose monitoring technical field, including panel, monitoring watch and winding rod, said monitoring watch top is equipped with panel, and the top end of panel is equipped with touch display screen, touch display screen top end is equipped with buzzer, and the panel top end is equipped with the buzzer. Threaded rods are installed on the inner walls of the two ends of the two sides of the panel, storage boxes are installed on the outer walls of the two sides of the monitoring watch, and winding rods are movably installed on the inner walls of the storage boxes through bearings. The pull rod is pulled outwards to enable the locking block to be far away from the locking groove, then the rotating rod is rotated to enable the winding rod to rotate at the same time, the winding rod rotates to enable the first watchband and the second watchband to be wound on the winding rod in the storage box, then the pull rod is loosened, the reset spring is reset to enable the locking block to be clamped in the locking groove, and the rotating rod is positioned. The first watchband and the second watchband are stored, so that the problem of inconvenience in carrying is solved.

The invention relates to a preparation method and application of sugar-responsive protamine insulin, which comprises the following steps: modifying a chemical group on cysteine of protamine, connecting with a phenylboronic acid compound to form a compound, and mixing with insulin to prepare the sugar-responsive protamine insulin. The sugar-responsive insulin preparation can realize an intelligent sugar-responsive regulation mechanism. Specifically, the insulin can be slowly released at a normal blood glucose level and is accelerated to be released at a hyperglycemia state, so that the blood glucose is effectively regulated and controlled, and the occurrence of hypoglycemia is avoided.

Provided herein are compositions and methods for treating post-bariatric hypoglycemia (PBH) in a subject in need thereof, including administration of an effective amount of avexitide.

The embodiment of the application discloses a blood glucose health dynamic regulation method and system based on an AI algorithm. The method comprises the following steps: acquiring first blood glucose data of a monitoring target in a current time window; acquiring at least one first feature map of blood glucose fluctuation of the monitoring target according to the first blood glucose data and second blood glucose data of at least one historical time window; generating a second feature map according to the first feature map and related information; obtaining a second prediction probability group according to the second feature map and a first prediction probability group of the at least one historical time window; the second prediction probability group comprises probabilities corresponding to different risk levels and confidence degrees corresponding to the probabilities; determining a risk level of the monitoring target in a next time window according to the second prediction probability group; the risk level comprises a first type of value and a second type of value; the first type of value is related to hypoglycemia; the second type of value is related to hyperglycemia; and storing the second prediction probability group into a first queue.

This invention relates to a method for preparing glucose-responsive protamine insulin and its application. The method involves modifying chemical groups on the cysteine ​​residues of protamine and linking them with phenylboronic acid compounds to form a complex, which is then mixed with insulin to prepare glucose-responsive protamine insulin. This glucose-responsive insulin formulation achieves an intelligent glucose response regulation mechanism. Specifically, under normal blood glucose levels, the insulin is released slowly, while under hyperglycemic conditions, its release is accelerated, thereby achieving effective blood glucose control and preventing hypoglycemia.